Arbutus Biopharma Highlights Imdusiran’s Potential in Hepatitis B

Arbutus Biopharma (ABUS) has released an update.

Arbutus Biopharma is set to showcase promising clinical data on its RNAi therapeutic, imdusiran, at The Liver Meeting 2024, highlighting its potential in treating chronic hepatitis B. The company’s research indicates that imdusiran effectively reduces hepatitis B surface antigen and supports the immune response, a crucial step towards a functional cure. The consistent success in clinical trials positions Arbutus as a significant player in the biopharmaceutical industry.

For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.